Skip to content

Adaptin BIO

1 viewer · 30d

Total raised

$1.9M

2 filings since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $1.9M
ROUNDS
2
INVESTORS
13
FOUNDED
2022
HQ
Charlotte, NC
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Adaptin Bio, Inc. is a clinical-stage biopharmaceutical company in Charlotte, North Carolina, co-founded and led by CEO Michael J. Roberts, Ph.D., with Simon Pedder, Ph.D. as executive chairman. Its BRiTE (Brain Bispecific T cell Engager) platform pairs a bispecific T cell engager with manipulated polyclonal T cells that act as "hitchhiking" carriers, ferrying therapeutics across the blood-brain barrier while activating an anti-tumor immune response. Lead candidate APTN-101 targets glioblastoma and has FDA clearance for a Phase 1 trial, with initial data expected in 2027. The company became quoted on the OTCQB under the ticker APTN in April 2026 after an alternative public offering and private placement.

What sets it apart

Instead of re-engineering a drug to cross the blood-brain barrier, Adaptin uses immune cells themselves as the delivery vehicle; preclinical work reported a more than sevenfold increase in delivery when the engager and manipulated T cells were used together, with high specificity against tumor-antigen-expressing glioma cells and no observed toxicity.

Funding history

2 rounds
EquityDec 22, 2025
Form D/A
+$1.7M$1.9M total
EquityDec 22, 2025
Form D/A
+$1.9M$1.9M total

Products

1 tracked

APTN-101

Clinical-stage therapeutic

The company's lead clinical candidate: a brain bispecific T cell engager combined with manipulated polyclonal T cells, in development for glioblastoma and other malignant gliomas.

  • Bispecific T cell engager paired with manipulated polyclonal T cells as delivery vehicles
  • Crosses the blood-brain barrier using patient-derived immune cells rather than a re-engineered molecule
  • Preclinical dose-dependent efficacy across multiple patient-derived malignant glioma lines with no observed toxicity
  • FDA clearance to begin a Phase 1 trial in glioblastoma, with initial data expected in 2027

Links

WebsiteLinkedInSEC EDGAR filings